Pfizer appoints chief oncology officer as new CSONovember 20, 2024 - Chris Boshoff will take over the role of chief scientific officer and president of research and development as of January 1, 2025. He rises from his position as chief oncology officer and executive vice president to oversee Pfizer’s entire R&D organization across all therapeutics areas. Boshoff has been with Pfizer for 11 years, working on 24 medicines and biosimilars in over 30 indications, Pfizer said
“Chris has a compelling vision for the future of R&D at Pfizer and deep knowledge of our entire pipeline and R&D organization that positions him well to succeed,” Pfizer CEO Albert Bourla said in a statement. “Under Chris’ leadership, oncology has become one of Pfizer’s most productive divisions and his continued supervision will ensure that we achieve our goal of being a global leader in oncology and other core therapeutic areas.”
https://www.biospace.com/business/pfizer-shakes-up-c-suite-elevating-cancer-chief-boshoff-to-cso